Gene-activated matrix harboring a miR20a-expressing plasmid promotes rat cranial bone augmentation

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Molecular Biology

Background:

• Gene-activated matrix (GAM) offers potential for sustained osteogenic protein release in bone engineering.
• Efficient non-viral methods for generating GAMs are needed.
• MicroRNA 20a (miR20a) may promote osteogenesis through multiple pathways.

Purpose of the Study:

• To investigate the efficacy of an atelocollagen-based GAM containing plasmid DNA encoding miR20a for rat cranial bone augmentation.
• To confirm the osteoblastic differentiation functions of pDNA encoding miR20a in vitro.
• To evaluate the in vivo bone augmentation and molecular changes induced by GAM transplantation.

Main Methods:

• Generated plasmid DNA (pDNA) encoding miR20a and confirmed its osteoblastic differentiation functions in vitro.
• Transfected rat bone marrow mesenchymal stem/progenitor cells (MSCs) with pmiR20a to assess gene expression changes.
• Fabricated atelocollagen-based GAMs with pDNA encoding miR20a and beta-TCP granules.
• Transplanted GAMs to rat cranial bone surfaces and evaluated bone augmentation and molecular markers up to 8 weeks.

Main Results:

• pmiR20a transfection regulated target genes (Bambi1, PPARγ) and increased BMP4 expression in rat MSCs.
• Transplantation of GAMs promoted significant vertical bone augmentation in rat cranial defects.
• Upregulation of VEGFs and BMP4 expression was observed at early stages post-transplantation.

Conclusions:

• Atelocollagen-based GAMs containing pDNA encoding miR20a facilitate rat cranial bone augmentation.
• GAM-based microRNA delivery represents a promising non-viral approach for enhancing transgene efficacy.
• This strategy holds potential for improving bone regeneration through the regulation of multiple osteogenic pathways.